TP53 (Ab-9) Antibody

What is the TP53 (Ab-9) Antibody and what epitope does it recognize?

TP53 (Ab-9) is a polyclonal antibody produced by immunizing rabbits with a synthetic peptide conjugated to KLH. It specifically recognizes a peptide sequence around amino acids 7-11 (D-P-S-V-E) derived from human p53 . This antibody detects endogenous levels of total p53 protein and is purified by affinity chromatography using an epitope-specific peptide .

What is the historical significance of p53 antibodies in cancer research?

Many discoveries in the p53 field have been attributed to antibodies generated against various domains, conformations, and modifications of p53. The discovery of p53 itself depended on detecting auto-antibody responses to p53 in animals bearing tumors . Early monoclonal antibodies like PAb122, PAb421, 200.47, and RA3 2C2 established that p53 accumulation is a common feature of transformed cells and played crucial roles in understanding p53's function in cell cycle regulation .

What applications is the TP53 (Ab-9) Antibody suitable for?

The TP53 (Ab-9) Antibody is primarily suitable for:

• Western blotting (WB) at dilutions of 1:500-1:1000

• Enzyme-linked immunosorbent assay (ELISA)

While some p53 antibodies are used for immunohistochemistry, immunoprecipitation, flow cytometry, and immunofluorescence , the specific validated applications for Ab-9 are WB and ELISA based on the search results.

What are the optimal storage conditions for TP53 (Ab-9) Antibody?

For long-term preservation, store at -20°C (recommended). For short-term use, store at 4°C . Upon receipt, the antibody should be stored at -20°C or -80°C, and repeated freeze-thaw cycles should be avoided . The antibody is supplied at 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol .

How can researchers verify the specificity of p53 antibodies in experimental procedures?

Specificity verification is crucial for p53 antibodies. Methods include:

• Competition assays: Using recombinant p53 protein to compete with the antibody binding to endogenous p53

• Testing on p53-null cell lines: Confirming absence of signal in p53-knockout or null cell lines

• Epitope mapping: Using synthetic peptide libraries and random phage display peptide libraries to precisely define epitope recognition

• Western blot analysis: Confirming the antibody detects a protein of the expected molecular weight (~53 kDa)

As demonstrated in large-scale studies, competition assays were used to ensure antibodies were specific to p53 protein when evaluating serum p53 antibodies in cancer patients .

What methodological considerations are important when using p53 antibodies for detecting different conformational states?

Research has shown that p53 can adopt different conformational states that affect its function:

• Antibodies to the carboxyl-terminal region (like PAb421 and PAb122) can enhance p53's DNA-binding ability by neutralizing negative regulatory effects of the p53 C-terminal region

• The use of monovalent Fab fragments combined with gel shifts incorporating antibodies like DO-1 showed that p53 binds to DNA as a tetramer

• Some antibodies (like ICA-9) can inhibit p53 DNA-binding that had been activated by other methods

• Certain N-terminal antibodies (like PAb1801) can reduce p53's rate of dissociation from DNA, thereby enhancing its ability to protect specific promoters

When studying p53 conformational states, researchers should select antibodies that recognize distinct epitopes that may be exposed or hidden in different functional states of the protein.

How are p53 antibodies used to distinguish between mutant and wild-type p53?

The distinction between mutant and wild-type p53 is crucial in cancer research:

• Some antibodies have been developed to be mutation-specific, recognizing common p53 mutational hotspots

• T cell receptor-like (TCRL) antibodies, such as P1C1TM, can distinguish between mutant and wild-type p53 expressing cells by recognizing p53-derived peptides presented on MHC molecules

• Immunohistochemistry (IHC) with certain p53 antibodies can detect the accumulation of mutant p53 protein, which is often more stable than wild-type p53

• Advanced approaches include engineering antibodies specific for p53 peptides presented by specific HLA alleles, allowing for targeted therapy against mutant p53-expressing tumors

This is particularly important as p53 mutations occur in approximately 50% of human cancers and mediate tumorigenesis .

How do p53 antibodies contribute to immune checkpoint inhibition research?

Research has revealed important connections between p53 and immunotherapy:

• p53 regulates the expression of immune checkpoint proteins like PD-L1

• In non-small cell lung cancer, p53-inducible miR-34 degrades PD-L1 mRNA

• In melanoma cells, p53 can positively regulate IFN-γ-induced PD-L1 expression by boosting JAK2 expression

• Antibodies targeting p53-derived peptide-MHCs can be used for immunotherapy against mutant p53-expressing tumors

These findings suggest that understanding p53 status is important when considering immune checkpoint inhibition strategies, and careful evaluation of PD-L1 expression after p53-activating therapies should be considered before administration of PD-L1-targeting therapy .

What is the role of p53 antibodies in detecting serum anti-p53 antibodies in cancer patients?

Serum p53 antibodies (S-p53-Abs) have been extensively studied as potential biomarkers:

• S-p53-Abs are found predominantly in human cancer patients with a specificity of 96%

• They are associated with p53 gene missense mutations and p53 accumulation in tumors, though the sensitivity is only about 30%

• The immune response is due to a self-immunization process linked to the immunogenicity of the p53 protein

• Highly specific, quantitative ELISA kits have been developed to detect these antibodies, with established cut-off values (e.g., 1.3 U/mL)

• In large studies, about 20.4% of cancer patients tested positive for S-p53-Abs, with the highest rates in head and neck carcinoma (32%), esophageal carcinoma (30%), and colorectal carcinoma (24%)

Meta-analyses have shown that serum p53 antibody testing has relatively reasonable diagnostic accuracy for breast, colorectal, esophageal, gastric, hepatic, lymphoma, lung, and ovarian cancers .

What factors influence the variability in p53 antibody immunostaining results?

Several factors contribute to variability in p53 antibody staining:

• Epitope accessibility: Different fixation methods can affect the exposure of p53 epitopes

• Species specificity: Some antibodies show exquisite species specificity due to single amino acid differences. For example, the DO-1 antibody binds to human but not mouse p53 due to a single amino acid change (D in human to G in mouse at position 21)

• Conformational changes: p53 undergoes conformational changes that can affect antibody binding

• Post-translational modifications: Phosphorylation and other modifications can alter antibody recognition

• Technical variability: Differences in antibody lots, incubation conditions, and detection systems

Understanding these factors is essential for accurate interpretation of experimental results.

What are the limitations of using serum p53 antibodies for cancer diagnosis?

Despite their high specificity, serum p53 antibodies have several limitations:

• Low sensitivity: Only about 30% of patients with p53 mutations develop detectable antibodies

• Type of mutation influence: Missense mutations are more likely to induce antibody production compared to other mutation types

• Individual immune response variation: The humoral response depends on the individual's immune system and MHC presentation

• Technical limitations: Anti-p53 antibodies lack sensitivity similar to immunohistochemistry because they are absent in patients where TP53 mutations negate p53 protein synthesis and accumulation

• Variable diagnostic value: While some cancer types show reasonable diagnostic accuracy, others have limited value when using s-p53 antibody testing

The diagnostic odds ratios (DOR) vary significantly between cancer types, ranging from 2.86 to 13.80, indicating heterogeneity in diagnostic performance across different cancers .

How should researchers interpret conflicting results between p53 antibody detection and other p53 assessment methods?

When faced with discrepancies between different p53 detection methods:

• Consider sequencing data: Direct sequencing of the TP53 gene remains the gold standard for determining mutation status

• Multiple epitope targeting: Use antibodies targeting different p53 domains (N-terminal, DNA-binding domain, C-terminal) as certain mutations might affect specific epitopes

• Functional assays: Consider using functional assays that assess p53 activity rather than just presence

• Conformational analysis: Some antibodies recognize specific conformational states of p53, which may not correlate with sequencing data

• Combined approach: A comprehensive assessment should include serum anti-p53 antibodies, immunohistochemistry, and sequencing to provide a complete picture of p53 status

Research indicates that while IHC of p53 protein and anti-p53 antibody status are valuable, they do not always correlate with clinical outcomes in cancer treatment .

How are p53 antibodies contributing to the development of targeted cancer therapies?

P53 antibodies are enabling several innovative therapeutic approaches:

• T cell receptor-like (TCRL) antibodies: Engineering antibodies like P1C1TM that specifically target p53-derived peptides presented by HLA class I molecules on tumor cells

• Antibody-drug conjugates: Cytotoxic PNU-159682-P1C1TM drug conjugates have shown specific inhibition of mutant p53 expressing cells in vitro and in vivo

• Antibody-dependent cellular cytotoxicity (ADCC): Engineered antibodies can mediate ADCC of mutant p53 expressing cells

• Early detection: Findings of p53 antibodies in high-risk individuals (like exposed workers or heavy smokers) indicate potential for early cancer detection

• P53-based vaccines: Clinical trials have evaluated p53-restoring compounds and p53-based vaccines with or without immune checkpoint inhibition

These approaches leverage the fact that elevated levels of p53-derived peptide-MHCs on tumor cells potentially differentiate them from healthy tissues, making them attractive targets for immunotherapy .

What role do p53 antibodies play in understanding p53's interaction with the immune system?

Research using p53 antibodies has revealed complex interactions between p53 and the immune system:

• Wild-type p53 regulates immune-related proteins including TRAIL, DR5, TLRs, Fas, PKR, ULBP1/2, and CCL2

• P53 can upregulate NK cell ligands like ULBP2, enhancing natural killer cell anti-tumor activity

• P53 activation can reverse immunosuppressed tumor microenvironments by eliminating myeloid-derived suppressor cells

• P53 mutations can contribute to immune evasion by influencing immune cell recruitment to tumors, cytokine secretion, and inflammatory signaling pathways

• Paradoxically, p53 mutations can increase neoantigen load, potentially improving response to immune checkpoint inhibition in some contexts

The development of specific p53 antibodies has been instrumental in elucidating these complex relationships, and continues to drive research into combined p53-targeting and immunotherapy approaches.

What methodological advances are improving the specificity and sensitivity of p53 antibody-based detection?

Recent advances in p53 antibody technology include:

• Highly specific quantitative ELISA kits: Development of standardized assays with defined cut-off values has improved reproducibility across laboratories

• Epitope-specific antibodies: Precise mapping of epitopes has led to antibodies that can distinguish between specific p53 conformations and post-translational modifications

• Combined biomarker approaches: Using serum p53 antibodies alongside other markers improves diagnostic accuracy

• Enhanced detection systems: More sensitive detection methodologies have lowered the limits of detection

• Meta-analysis of diagnostic value: Large-scale studies involving thousands of patients have established the diagnostic precision of serum p53 antibodies across different cancer types

Meta-analysis of 100 eligible studies with 23 different types of tumors established serum p53 antibody testing has a positive likelihood ratio of 5.75 (95% CI: 4.60–7.19) and diagnostic odds ratio of 7.56 (95% CI: 6.02–9.50) , providing statistical foundation for its clinical utility.